Veterinary Oncology Market Size To Reach $3.11 Billion By 2030

Veterinary Oncology Market Growth & Trends

The global veterinary oncology market size is expected to reach USD 3.11 billion in 2030 and is projected to grow at a CAGR of 12.08% from 2025 to 2030. Increasing prevalence of cancer in pets and demand for veterinary diagnostics are projected to drive the market over the forecast period.

Adoption of canine cancer registry globally to estimate cancer incidences is another driving factor for the market growth. According to frontiers in Veterinary Science in February 2019, the Swiss Canine Cancer Registry (SCCR) was used as a data source and was compiled for future comparative studies of canine and human cancers. This database is further helpful in mitigating the incidence of malignant tumors in the human population, thereby driving the market growth.

Researchers carrying out studies focused on veterinary oncology are further boosting the veterinary oncology market growth. For instance, University of Illinois in August 2017, carried out study that involves more precise detection of metastasis (spread of cancer through the body) for head and neck tumors in dogs. Moreover, the market players are also focusing on new product innovation and strategic collaborations. For instance, in 2018 AdvaVet, a subsidiary of Oasmia Pharmaceutical AB, developed XR17 technology, which is nanoparticle formulation based that makes a single Active Pharmaceutical Ingredient (API) or multiple APIs water soluble. It is a combination therapy and is also a standard treatment for a number of cancer diseases in pet animals. 

 Request a free sample copy or view report summary: Veterinary Oncology Market Report

Veterinary Oncology Market Report Highlights

• Increasing prevalence of cancer in companion animals, several clinical trial studies to evaluate the safety and effectiveness of cancer therapeutics for pets and technological advancements in veterinary oncology treatment are anticipated to create growth opportunities in the market.

• Chemotherapy accounted for the largest revenue share over the coming years, owing to its increasing adoption for pet cancer treatment either alone or in combination with other therapies.

• The canine segment held the largest revenue share of over 86.09% in 2024, increasing the population of dogs and high prevalence of cancer in dogs as compared to cats.

• North America held the dominant share as of 2024, due to the favorable government policies, new product launch by the companies, and huge investment for veterinary oncology treatment.

• Asia Pacific is anticipated to witness lucrative growth due to increasing focus on animal health and expenditure, increasing number of pet population being exposed to cancer, government focus on animal safety, and several initiatives to curb cancer cases in pet animals.

Veterinary Oncology Market Segmentation

Grand View Research has segmented the global Veterinary Oncology market report based on product, type of waste, end use, and region:

Veterinary Oncology Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

• Canine

• Feline

• Equine

Veterinary Oncology Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Radiotherapy 

  • Stereotactic Radiation Therapy

    • LINAC

    • Other Types

  • Conventional Radiation Therapy

  • Surgery

  • Chemotherapy

  • Immunotherapy

  • Other Therapies

Veterinary Oncology Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)

• Skin Cancers

• Lymphomas

• Sarcomas

• Others

Veterinary Oncology Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Rest of EU

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

  • Rest of APAC

• Latin America

  • Brazil

  • Argentina

  • Rest of LA

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Rest of MEA

List of Key Players in Veterinary Oncology Market

• Elanco

• Boehringer Ingelheim International GmbH

• Zoetis

• Elekta AB

• PetCure Oncology

• Accuray Incorporated

• Varian Medical Systems, Inc. (parent company: Siemens Healthineers)

• Virbac

• Merck & Co., Inc.

• Dechra Pharmaceuticals PLC

• NovaVive Inc.

• Ardent Animal Health, LLC (A BreakthrU Company)